Have a feature idea you'd love to see implemented? Let us know!

AGIO Agios Pharmaceuticals Inc

Price (delayed)

$59.02

Market cap

$3.37B

P/E Ratio

5.01

Dividend/share

N/A

EPS

$11.79

Enterprise value

$3.17B

Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In ...

Highlights
Agios Pharmaceuticals's equity has surged by 146% QoQ and by 83% YoY
Agios Pharmaceuticals's gross profit has increased by 38% YoY and by 5% QoQ
The quick ratio is down by 24% year-on-year and by 8% since the previous quarter

Key stats

What are the main financial stats of AGIO
Market
Shares outstanding
57.03M
Market cap
$3.37B
Enterprise value
$3.17B
Valuations
Price to earnings (P/E)
5.01
Price to book (P/B)
2.06
Price to sales (P/S)
102.23
EV/EBIT
4.36
EV/EBITDA
4.26
EV/Sales
96.53
Earnings
Revenue
$32.87M
EBIT
$727.43M
EBITDA
$744.44M
Free cash flow
-$330.07M
Per share
EPS
$11.79
Free cash flow per share
-$5.8
Book value per share
$28.59
Revenue per share
$0.58
TBVPS
$31.47
Balance sheet
Total assets
$1.79B
Total liabilities
$165.12M
Debt
$60.83M
Equity
$1.63B
Working capital
$954.74M
Liquidity
Debt to equity
0.04
Current ratio
8.99
Quick ratio
8.44
Net debt/EBITDA
-0.26
Margins
EBITDA margin
2,264.7%
Gross margin
89.4%
Net margin
2,051.4%
Operating margin
1,466.8%
Efficiency
Return on assets
62%
Return on equity
70.2%
Return on invested capital
77.2%
Return on capital employed
43.5%
Return on sales
2,213%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AGIO stock price

How has the Agios Pharmaceuticals stock price performed over time
Intraday
-2.38%
1 week
26.38%
1 month
38.38%
1 year
179.19%
YTD
165.02%
QTD
32.84%

Financial performance

How have Agios Pharmaceuticals's revenue and profit performed over time
Revenue
$32.87M
Gross profit
$29.38M
Operating income
$482.16M
Net income
$674.31M
Gross margin
89.4%
Net margin
2,051.4%
Agios Pharmaceuticals's gross profit has increased by 38% YoY and by 5% QoQ
The revenue has grown by 37% year-on-year and by 5% since the previous quarter

Growth

What is Agios Pharmaceuticals's growth rate over time

Valuation

What is Agios Pharmaceuticals stock price valuation
P/E
5.01
P/B
2.06
P/S
102.23
EV/EBIT
4.36
EV/EBITDA
4.26
EV/Sales
96.53
Agios Pharmaceuticals's equity has surged by 146% QoQ and by 83% YoY
The P/B is 24% below the 5-year quarterly average of 2.7 and 10% below the last 4 quarters average of 2.3
AGIO's P/S is 59% above its last 4 quarters average of 64.4
The revenue has grown by 37% year-on-year and by 5% since the previous quarter

Efficiency

How efficient is Agios Pharmaceuticals business performance

Dividends

What is AGIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AGIO.

Financial health

How did Agios Pharmaceuticals financials performed over time
The total assets has surged by 132% since the previous quarter and by 78% year-on-year
The total liabilities has increased by 47% since the previous quarter and by 37% year-on-year
The debt is 96% smaller than the equity
Agios Pharmaceuticals's equity has surged by 146% QoQ and by 83% YoY
The debt to equity has shrunk by 60% QoQ and by 56% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.